SVB Leerink raised the price target for the AbCellera Biologics Inc. (NASDAQ:ABCL) stock to “an Outperform”. The rating was released on January 05, 2021. The research report from Credit Suisse has initiated the stock to Outperform, with a price target set at $52. The stock was initiated by BMO Capital Markets, who disclosed in a research note on January 05, 2021, to Outperform and set the price objective to $48. In their research brief published January 05, 2021, Berenberg analysts initiated the AbCellera Biologics Inc. stock to Buy with a price target of $53.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of $0.44 during the last quarter as opposed to a consensus estimate of $0.61, which indicates the company missed its estimate by -$0.17, which implies that the company surprised the market by -27.90%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is $0.38. This is an average of 4 analysts’ earnings, where the high earnings per share estimate is $0.41 and the low earnings per share estimate is $0.36. According to 4 analyst estimates, an average revenue estimate of $196.48M is projected for the current quarter with a high revenue estimate of $208.04M and a low estimate of $187.86M.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of AbCellera Biologics Inc. (NASDAQ:ABCL) dipped -7.40% to close Friday’s market session at $26.65, lower as compared to yesterday’s close. The stock price fluctuated between $26.50 and $29.07 throughout the trading session with the volume trading being 1062202 shares, which represented a significant variation when compared to the three months average volume of 1.07 million shares. The firm’s stock price fluctuated -9.14% within the last five trades and -21.53% within the last 30 trades, which was a significant change from the beginning of this year. ABCL stock is trading at a margin of -9.07%, -16.79% and -30.76% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ABCL deals in the Healthcare domain. The stock is trading -62.94 percent below its 52-week high and 14.87 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is null. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does AbCellera Biologics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 71.50 percent and the profit margin is 54.50 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $7.80 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for AbCellera Biologics Inc. (NASDAQ:ABCL) is 110.58. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 94.50. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 35.73 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 18.90, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 23.50 percent of AbCellera Biologics Inc. shares are owned by insiders, and 38.20 percent are held by financial institutions.